Methotrexate Ebewe Datasheet

WARNINGS

METHOTREXATE EBEWE (METHOTREXATE 100 MG/ML) IS RECOMMENDED FOR INTRAVENOUS ADMINISTRATION ONLY.

METHOTREXATE MUST BE USED ONLY BY DOCTORS EXPERIENCED IN ANTIMETABOLITE CHEMOTHERAPY OR IN THE CASE OF NON-ONCOLOGICAL CONDITIONS, BY A SPECIALIST DOCTOR.

BECAUSE OF THE POSSIBILITY OF FATAL OR SEVERE TOXIC REACTIONS THE PATIENT SHOULD BE FULLY INFORMED BY THE DOCTOR OF THE RISKS INVOLVED AND SHOULD BE UNDER HIS CONSTANT SUPERVISION.

DEATHS HAVE BEEN REPORTED WITH THE USE OF METHOTREXATE.

IN THE TREATMENT OF PSORIASIS, METHOTREXATE USE SHOULD BE RESTRICTED TO SEVERE, RECALCITRANT, DISABLING DISEASE THAT IS NOT ADEQUATELY RESPONSIVE TO OTHER FORMS OF THERAPY, AND ONLY WHEN THE DIAGNOSIS HAS BEEN ESTABLISHED, BY BIOPSY AND/OR AFTER APPROPRIATE CONSULTATION.

1. Methotrexate may produce marked depression of the bone marrow, anaemia, aplastic anaemia, leucopenia, neutropenia, thrombocytopenia and bleeding.

2. Methotrexate may be hepatotoxic, particularly at high dosage or with prolonged therapy. Liver atrophy, necrosis, cirrhosis, fatty changes and periportal fibrosis have been reported. Since changes may occur without previous signs of gastrointestinal or haematological toxicity, it is imperative that hepatic function be determined prior to initiation of treatment and monitored regularly throughout therapy. Special caution is indicated in the presence of pre-existing liver damage or impaired hepatic function. Concomitant use of methotrexate with other drugs with hepatotoxic potential or alcohol should be avoided.

3. Malignant lymphomas, which may regress following withdrawal of methotrexate, may occur in patients receiving low dose methotrexate and, thus, may not require cytotoxic treatment. Discontinue methotrexate first and, if the lymphoma does not regress, appropriate treatment should be instituted.

4. Potentially fatal opportunistic infections, especially Pneumocystis carinii pneumonia, may occur with methotrexate therapy.

5. Methotrexate given concomitantly with radiotherapy may increase the risk of soft tissue necrosis and osteonecrosis.

6. Unexpectedly severe (sometimes fatal) marrow suppression, aplastic anaemia and gastrointestinal toxicity have been reported with concomitant administration of methotrexate (usually in high doses) with nonsteroidal anti-inflammatory drugs (NSAIDs).
7. Diarrhoea and ulcerative stomatitis are frequent toxic effects and require interruption of therapy, otherwise haemorrhagic enteritis and death from intestinal perforation may occur.

8. Pulmonary toxicity including pneumonitis and pulmonary fibrosis, which can progress rapidly and is potentially fatal, has been associated with methotrexate therapy. It may occur acutely at any time during therapy and has been reported at low doses. Methotrexate should be discontinued and careful clinical evaluation be performed in patients developing symptoms of pulmonary toxicity (e.g. dry, non-productive cough and dyspnoea). Pulmonary lesions can occur at all dosages. Infection (including pneumonia) needs to be excluded. Management of methotrexate induced pulmonary toxicity is mainly supportive. Methotrexate induced pulmonary toxicity may not be fully reversible. Patients should be closely monitored for pulmonary symptoms. Infection (including pneumonia) needs to be excluded in patients presenting with symptoms of pulmonary toxicity.

9. Methotrexate has been used in high dosage schedules followed by calcium folinate (leucovorin calcium) in the adjuvant treatment of certain neoplastic diseases. This procedure is complicated and hazardous. It should not be attempted except by highly experienced teams following carefully designed protocols. The recent published literature should always be consulted.

10. **Impaired Renal function** Methotrexate is usually contraindicated in patients with impaired renal function.

11. **Use in pregnancy** (Category D)
    Methotrexate has caused foetal death and/or congenital anomalies. It should not be used in pregnant women, or in those who might become pregnant, unless the potential benefits can be expected to outweigh the considered risks. Methotrexate is contraindicated in the treatment of psoriasis in pregnant women. Women of childbearing potential should not be started on methotrexate until pregnancy is excluded and should be fully counselled on the serious risk to the fetus should they become pregnant while undergoing treatment. Pregnancy should be avoided if either partner is receiving methotrexate, during and for a minimum of three months after therapy has ceased.

12. **Use in lactation**
    Women should be advised not to breastfeed while being treated with Methotrexate.

13. **Use in children**
    Aside from its established use in cancer chemotherapy, the safety and efficacy of using methotrexate in children has not been fully elucidated.
NAME OF THE MEDICINE
Methotrexate injection concentrate

Composition
Active: Methotrexate BP

Chemical name: (S)-2-[4-[(2,4-diaminopteridin -6-ylmethyl) methylamino] benzoymlamido] pentanedioic acid. C_{20}H_{22}N_{8}O_{5}
Molecular weight: 454.4
CAS: 59-05-2

DESCRIPTION
Methotrexate is a yellow or orange, crystalline powder, practically insoluble in water, in alcohol, in ether and in methylene chloride. It dissolves in dilute solutions of mineral acids and in dilute solutions of alkali hydroxides and carbonates.

PHARMACOLOGY
Methotrexate exerts its cytotoxic effect through competitive inhibition of dihydrofolate reductase, the enzyme that reduces folic acid to tetrahydrofolic acid. Inhibition of tetrahydrofolic acid results in interference with DNA synthesis and cellular reproduction.

Tissues with high rates of cellular proliferation, e.g. malignant cells, bone marrow, foetal cells, dermal epithelium, buccal and intestinal mucosa and cells of the urinary bladder are generally more sensitive to this effect of methotrexate.

In psoriasis, the rate of production of epithelial cells in the skin is greatly increased over normal skin. This differential in reproductive rates provides the basis for use of methotrexate to control the psoriatic process.

Pharmacokinetics
After parenteral injection, peak serum levels are seen in about 0.5 to 2.0 hours. Approximately one-half the absorbed methotrexate is reversibly bound to serum protein, but exchanges with body fluids easily and diffuses into the body tissue cells. Elimination is triphasic. The first phase probably describes distribution into organs; the second, renal excretion; and the third, passing of methotrexate into the enterohepatic circulation. Excretion occurs mainly through the kidneys. Approximately 41% of the dose is excreted unchanged in the urine during the first six hours; 90% within 24 hours. Repeated daily doses result in more sustained serum levels and some retention of methotrexate over each 24 hour period which may result in accumulation of the medicine within the tissues. The liver cells appear to retain certain amounts of the medicine for prolonged periods even after a single therapeutic dose. Methotrexate is retained in the presence of impaired renal function and may
increase rapidly in the serum and in the tissue cells under such conditions. Methotrexate does not penetrate the blood cerebrospinal fluid barrier in therapeutic amounts when given parenterally. High concentrations of the medicine when needed may be attained by direct intrathecal administration. However, Methotrexate Ebewe is not suitable for intrathecal administration.

**INDICATIONS**

**Antineoplastic chemotherapy.** Methotrexate has a broad spectrum of antineoplastic activity. It is indicated for the treatment of breast cancer and the palliation of acute and subacute lymphocytic leukaemia (greatest effect has been observed in palliation of acute lymphoblastic (stem-cell) leukaemias). Methotrexate is now most commonly used for the maintenance of medicine induced remissions.

**High dose therapy.** In high dose schedules, methotrexate may be effective alone or in combination therapy, in the treatment of epidermoid cancers of the head and neck, osteogenic sarcoma and bronchogenic carcinoma. Calcium folinate (leucovorin calcium) must be used in conjunction with high dose methotrexate therapy.

**Psoriasis chemotherapy.** (See Warnings box.) Methotrexate may be of value in the symptomatic control of severe, recalcitrant, disabling psoriasis that is not adequately responsive to other forms of treatment. However, due to the high risk associated with its use, methotrexate should be used after the diagnosis has been definitely established, as by biopsy and/or after dermatological consultation.

**CONTRAINDICATIONS**

- Severe renal impairment.
- In patients being treated for psoriasis: pregnancy; poor nutritional status; bone marrow depression; hepatic disorders; pre-existing blood dyscrasias (e.g. bone marrow hypoplasia, leucopenia, thrombocytopenia or anaemia).
- Psoriasis patients with serious infections, peptic ulcer disease or ulcerative colitis. Methotrexate is contraindicated in psoriatic patients suffering severe renal disorders, alcoholism or hepatic disorders including alcoholic liver disease or other chronic liver disease.
- Overt or laboratory evidence of immunodeficiency syndrome(s).
- Breastfeeding.
- Known hypersensitivity to methotrexate or any of the excipients.
- An increased risk of hepatitis has been reported to result from combined use of methotrexate and etretinate. Therefore, the combination of methotrexate and acitretin is also contraindicated.

**PRECAUTIONS**

Methotrexate Ebewe (methotrexate 100 mg/mL) is recommended for intravenous administration only.

Methotrexate must only be used by doctors experienced in antimetabolite chemotherapy or, in the case of nononcological conditions, by a specialist doctor.

Methotrexate has a high potential for toxicity which is usually dose related. The doctor should be familiar with the various characteristics of the medicine and its established clinical usage. Because the toxic effects can occur at any time during methotrexate therapy, patients must be kept under appropriate supervision so that signs or symptoms of possible toxicity or adverse reactions may be detected as early as possible. This is especially important in patients undergoing high dose therapy or
in those where medicine elimination could be impaired (renal impairment, pleural effusion, ascites). When such reactions do occur, the medicine should be reduced in dosage or discontinued and appropriate corrective measures should be taken. If methotrexate therapy is reintroduced, it should be carried out with utmost caution, with adequate consideration of further need for the medicine, and with increased alertness as to possible recurrence of toxicity.

Pretreatment and periodic haematological evaluations are essential to the use of methotrexate in chemotherapy because of its haemopoietic suppressive effects, manifesting as anaemia, aplastic anaemia, pancytopenia, leukopenia, neutropenia and/or thrombocytopenia. This may occur abruptly and on apparent safe dosage, and any profound drop in blood cell count indicates immediate cessation of the medicine and appropriate therapy. Methotrexate should be used with caution, if at all, in patients with malignant disease who have pre-existing bone marrow aplasia, leucopenia, thrombocytopenia, or anaemia.

Patients with leukaemia are subject to leukaemic invasion of the central nervous system. This may manifest characteristic signs or symptoms or may remain silent and be diagnosed only by examination of the cerebrospinal fluid, which contains leukaemic cells in such cases. Therefore, the CSF should be examined in all leukaemic patients. Since passage of methotrexate from blood serum to the cerebrospinal fluid is minimal, for adequate therapy methotrexate is administered intrathecally. Methotrexate Ebewe is not suitable for intrathecal administration. If intrathecal methotrexate therapy is indicated, a suitable alternative formulation should be used.

Check the following before and during use. As methotrexate is excreted primarily by the kidney, its use in the presence of impaired renal function may lead to medicine accumulation with resultant toxicity or even additional renal damage. The renal status of the patient should be determined prior to and during methotrexate therapy. Caution should be exercised if significant renal impairment is present. Medicine dosage should be reduced or discontinued until renal function is improved or restored. The urine should be kept alkaline throughout therapy with methotrexate (methotrexate is a weak acid and tends to precipitate at urine pH below 6.0).

Methotrexate may cause renal damage that may lead to acute renal failure. Close attention to renal function including adequate hydration, urine alkalinization, and measurement of serum methotrexate and renal function are recommended.

If vomiting, diarrhoea or stomatitis occur, resulting in dehydration, methotrexate should be discontinued until recovery occurs.

Methotrexate has been associated with pulmonary toxicity which is potentially fatal. Patients should be closely monitored for pulmonary symptoms. The medicine should be discontinued and careful clinical evaluation should be performed in patients developing pulmonary manifestations (especially a dry, nonproductive cough). Although clinically variable, the typical patient with methotrexate induced lung disease presents with fever, cough, chest pain, dyspnoea, hypoxaemia and an infiltrate on X-ray; infection (including pneumonia) needs to be excluded. This lesion can occur at all dosages. (See Warning box.)

The following laboratory tests should be carried out as part of the clinical evaluation and appropriate monitoring of patients on methotrexate therapy: complete haemogram; haematocrit; urinalysis; renal and liver function tests. A chest X-ray is recommended. The tests should be performed prior to, during and after therapy.
During initial or changing doses, or during periods of increased risk of elevated methotrexate levels (e.g. dehydration) more frequent monitoring may also be indicated. During therapy for psoriasis, monitoring of the following parameters is recommended: haematology at least monthly, liver and renal function every one to two months. More frequent monitoring is usually indicated during antineoplastic therapy. It is important to perform liver biopsy or bone marrow aspiration studies where high dose or long-term therapy is being followed. Pulmonary function tests may be useful if methotrexate induced lung disease is suspected, especially if baseline measurements are available.

Methotrexate should be used with extreme caution in the presence of infection, peptic ulcer, ulcerative colitis, debility, and in extreme youth and old age.

Like other cytotoxic medicines, methotrexate may induce tumour lysis syndrome in patients with rapidly growing tumours. Appropriate supportive and pharmacological measures may prevent or alleviate this complication.

Methotrexate exits slowly from the third space compartments (e.g. pleural effusions or ascites). This results in a prolonged terminal phase half-life and unexpected toxicity. In patients with significant third space accumulation, it is advisable to evacuate the fluid before treatment and to monitor plasma methotrexate levels.

Methotrexate causes hepatotoxicity, liver fibrosis and cirrhosis, but generally only after prolonged use. Transient abnormalities of liver function tests (elevated transaminases) are observed frequently but persistent abnormalities and/or significant decreases in serum albumin may indicate serious liver toxicity and require evaluation. Liver biopsy is currently believed to be the only reliable measure of methotrexate-induced hepatotoxicity. Liver biopsy after sustained use often shows histological changes, and fibrosis and cirrhosis have been reported; these latter lesions may not be preceded by symptoms or abnormal liver function tests in the psoriasis population. Periodic liver biopsies are usually recommended for psoriatic patients who are under long-term treatment.

The risk of developing acute hepatitis and chronic hepatotoxicity in psoriatic patients seems to be correlated not only to the cumulative dose of the medicine but also to the presence of concurrent conditions such as alcoholism, obesity, diabetes, advanced age and arsenical compounds. Chronic toxicity is potentially fatal; it generally has occurred after prolonged use (generally two years or more) and after a total cumulative dose of at least 1.5 g.

In psoriasis, liver damage and function tests, including serum albumin and prothrombin time, should be performed several times prior to dosing. Liver function tests are often normal in developing fibrosis or cirrhosis. These lesions may be detectable only by biopsy. It is recommended to obtain a liver biopsy at: before start of therapy or shortly after initiation of therapy (two to four months); after a total cumulative dose of 1.5 g; and after each additional 1.0 to 1.5 g. In case of moderate fibrosis or any cirrhosis, discontinue the medicine; mild fibrosis normally suggests a repeat biopsy in six months. Milder histological findings such as fatty change and low grade portal inflammation are relatively common before the start of therapy. Although these mild changes are usually not a reason to avoid or discontinue methotrexate therapy, the medicine should be used with caution.

Pretreatment liver biopsy should be performed for patients with a history of excessive alcohol consumption, persistently abnormal baseline liver function test values, or chronic hepatitis B or C infection. During therapy, liver biopsy should be performed if
there are persistent liver function test abnormalities, or there is a decrease in serum albumin below the normal range.

If the results of a liver biopsy show mild changes (Roenigk grades I, II, IIIa), methotrexate may be continued and the patient monitored according to the recommendations listed above. Methotrexate should be discontinued in any patient who displays persistently abnormal liver function tests and refuses liver biopsy, or in any patient whose liver biopsy shows moderate to severe changes (Roenigk grade IIIb or IV).

Methotrexate therapy has immunosuppressive activity, which can potentially lead to serious or even fatal infections. Bacterial infection may occur or be a threat if profound leucopenia occurs during therapy. In this instance, the medicine should be discontinued and appropriate antibiotic therapy instituted. If severe bone marrow depression occurs, blood or platelet transfusions may be required. Potentially fatal opportunistic infections, especially Pneumocystis carinii pneumonia, may occur with methotrexate therapy. When a patient presents with pulmonary symptoms, the possibility of Pneumocystis carinii pneumonia should be considered. The immunosuppressive action of methotrexate must be taken into consideration in evaluating the use of the medicine where immune responses in a patient may be important or essential.

Immunisation may be ineffective when given during methotrexate therapy. Immunisation with live virus vaccines is generally not recommended. There have been reports of disseminated vaccinia infections after smallpox immunisation in patients receiving methotrexate therapy (see Interactions).

Severe, occasionally fatal, skin reactions have been reported following single or multiple doses of methotrexate. Reactions have occurred within days of administration. Recovery has been reported with discontinuation of therapy.

When considering the use of methotrexate for chemotherapy, clinicians must evaluate the need and potential value of the medicine against the risks, adverse reactions or toxic effects. Most adverse reactions are reversible if detected early. When such reactions do occur, the dosage should be reduced or medicine discontinued and appropriate corrective measures taken. If necessary, this could include the use of leucovorin calcium and/or acute intermittent haemodialysis with a high flux dialyser. Caution should be exercised when reinstituting methotrexate therapy and adequate consideration given to the need for further medicine administration and alertness to the possible recurrence of toxicity.

**High dose therapy.** Methotrexate has been used in very high dosage followed by leucovorin (calcium folinate) rescue in the experimental treatment of certain neoplastic disease. This procedure is investigational and hazardous. It should not be attempted outside of facilities where the necessary expertise and resources have been assembled. The recent published literature should be consulted.

Large doses should not be used in patients with impaired renal function or a third space reservoir such as ascites or large pleural effusion. Renal function and serum levels should be carefully monitored in order to reveal potential toxicity. Administration of calcium folinate is mandatory in high dose methotrexate therapy. The administration of calcium folinate, hydration and alkalisation of the urine should be carried out with constant monitoring of the toxic effects and the elimination of methotrexate in order to prevent renal precipitation in acidic urine.
Transient abnormalities of liver function tests (elevated transaminases) are observed frequently but persistent abnormalities and/or significant decreases in serum albumin may indicate serious hepatic toxicity and require evaluation. Liver biopsy is currently believed to be the only reliable measure of methotrexate induced hepatotoxicity.

**Use in the elderly.** Due to diminished hepatic and renal functions as well as decreased folate states in elderly patients, relatively low doses should be considered and these patients should be closely monitored.

**Carcinogenesis, mutagenesis, impairment of fertility.** No controlled human data exist regarding the risk of neoplasia with methotrexate. Methotrexate has been evaluated in a number of animal studies for carcinogenic potential with inconclusive results. There is evidence that methotrexate causes chromosomal damage to animal somatic cells and human bone marrow cells.

Methotrexate *in vitro* caused chromosomal aberrations in Chinese hamster A(T1)C1-3 cells, induced morphological transformation in mouse C3H/10T1/1 clone 8 cells and was associated with an increased incidence of large colony mutants at the tk locus in L5178Y/tk+ mouse lymphoma cells. *In vivo*, it caused an increased incidence in polychromatic erythrocytes in mice and in human bone marrow cells a transient and reversible increase in chromosomal aberrations. The clinical significance of these findings is uncertain.

Benefit should be weighed against this potential risk before using methotrexate alone or in combination with other medicines, especially in children or young adults. Methotrexate causes embryotoxicity, abortion and foetal defects in humans. It has also been reported to cause impairment of fertility, oligospermia and menstrual dysfunction in humans, during and for a short period after cessation of therapy. Methotrexate may cause defective oogenesis and spermatogenesis. Therefore, in men and women of fertile age, steps should be taken to avoid conception during methotrexate therapy. The risk of genetic abnormalities may persist after discontinuing methotrexate therapy. Thus it is advised that both men and women avoid intercourse leading to conception for an indefinite period (at least twelve weeks) after discontinuing methotrexate, to ensure the re-establishment of normal germinal cells.
Use in pregnancy. (Category D)
Methotrexate has caused foetal death and/or congenital abnormalities; therefore, it is not recommended in women of childbearing potential unless there is appropriate medical evidence that the benefits can be expected to outweigh the considered risks. Pregnant psoriatic patients should not receive methotrexate. Women of childbearing potential should not be started on methotrexate until pregnancy is excluded and should be fully counselled on the serious risk to the fetus should they become pregnant while undergoing treatment. Pregnancy should be avoided if either partner is receiving methotrexate, during and for at least twelve weeks after cessation of therapy.

Use in lactation. Women should be advised not to breastfeed while being treated with methotrexate.

Ability to drive or operate machinery
Adverse reactions to methotrexate, such as dizziness and fatigue may affect the ability to drive or operate machinery.

Instructions to patients. Patients should be informed of the potential benefit and risk in the use of methotrexate. The risk of effects on reproduction should be discussed with both male and female patients taking methotrexate.

Patients should be informed of the early signs and symptoms of toxicity, the need to see their doctor promptly if they occur, and the need for close follow-up, including periodic laboratory tests to monitor toxicity.

Patients receiving methotrexate should avoid excessive unprotected exposure to sun or sunlamps because of possible photosensitivity reactions.

Interactions
As methotrexate is partly bound to serum proteins, its toxicity may be increased as a result of displacement by certain medicines, e.g. salicylates, phenylbutazone, sulfonamides, sulfonylureas, phenytoin, tetracyclines, chloramphenicol and para-aminobenzoic acid. These medicines, particularly salicylates and sulfonamides, should not be given concurrently until the significance of these findings is established. Renal tubular transport is diminished by probenecid; use of methotrexate with this medicine should be carefully monitored.

The excretion of methotrexate from the body can be markedly reduced by the concurrent use of penicillins and sulfonamides. There is a considerable risk of methotrexate toxicity. Increased serum concentrations of methotrexate with concomitant haematologic and gastrointestinal toxicity have been observed. Use of methotrexate with penicillins and sulfonamides should be carefully monitored.

Hypolipidaemic compounds such as cholestyramine provided preferential binding sites compared to serum proteins when given in combination with methotrexate. This may lead to decreased methotrexate serum levels.

Vitamin preparations containing folic acid or its derivatives may decrease the effectiveness or alter responses to methotrexate and should not be given concomitantly.

Nonsteroidal anti-inflammatory drugs (NSAIDs) should not be administered prior to or concomitantly with high doses of methotrexate. NSAIDs elevate and prolong serum methotrexate levels, resulting in death from severe haematological and
gastrointestinal toxicity. These unexpectedly severe toxicities have been reported with concomitant administration of methotrexate and aspirin, other salicylates, asapropazone, diclofenac, indomethacin and ketoprofen. Naproxen has been reported not to affect the pharmacokinetics of methotrexate but a fatal interaction has been reported.

Caution should be used when NSAIDs or salicylates are administered concomitantly with lower doses of methotrexate. These medicines have been reported to reduce the tubular secretion of methotrexate in an animal model and may enhance its toxicity.

Therefore, until more is known about the NSAID/ methotrexate interaction, it is recommended that methotrexate dosage be carefully controlled during treatment with NSAIDs.

Proton-pump inhibitors - Use caution when administering high-dose methotrexate to patients receiving proton pump inhibitor (PPI) therapy. Case reports and published population pharmacokinetic studies suggest that concomitant use of some PPIs, such as omeprazole, esomeprazole, and pantoprazole, with methotrexate (primarily at high dose), may elevate and prolong serum levels of methotrexate and/or its metabolite hydromethotrexate, possibly leading to methotrexate toxicities.

Probenecid may cause the methotrexate plasma half-life to increase and therefore blood levels of methotrexate to increase.

Concomitant use of allopurinol with methotrexate may result in an increased incidence of cytotoxic induced bone marrow depression.

In the treatment of patients with osteosarcoma, caution must be exercised if high dose methotrexate is administered in combination with a potentially nephrotoxic chemotherapeutic agent, e.g. cisplatin.

Methotrexate is often used in combination with other cytotoxic medicines. Additive toxicity may be expected in chemotherapy regimens which combine medicines with similar pharmacological effects and special monitoring should be performed with regard to bone marrow depression, and renal, gastrointestinal, pulmonary toxicity. The dosage of methotrexate should be adjusted if it is used in combination with other chemotherapeutic agents with overlapping toxicities.

Folate deficiency states may increase methotrexate toxicity. Trimethoprim alone, sulfamethoxazole/ trimethoprim and pyrimethamine have been reported rarely to increase the toxic effects (e.g. bone marrow suppression) of methotrexate, probably by an additive antifolate effect.

The use of nitrous oxide anaesthesia potentiates the effect of methotrexate on folate metabolism, yielding severe, unpredictable myelosuppression and stomatitis. This effect can be reduced by the use of calcium folinate.

Methotrexate in combination with leflunomide may also increase the risk of pancytopenia and interstitial pneumonitis.

**Assay for folate.** Methotrexate may inhibit the organism used in the assay and interfere with detection of folic acid deficiency.
Amiodarone administration to patients receiving methotrexate treatment for psoriasis has induced ulcerative skin lesions.

An increased risk of hepatotoxicity has been reported when methotrexate and etretinate are given concurrently (see Contraindications).

The potential for increased hepatotoxicity when methotrexate is administered with other hepatotoxic agents has not been evaluated. However, hepatotoxicity has been reported in such cases. Therefore, patients receiving concomitant therapy with methotrexate and other potential hepatotoxins (e.g. leflunomide, azathioprine, retinoids, sulfasalazine) should be closely monitored for possible increased risk of hepatotoxicity. Methotrexate in combination with leflunomide may also increase the risk of pancytopenia.

Methotrexate may decrease the clearance of theophylline; theophylline levels should be monitored when used concurrently with methotrexate.

Methotrexate increases the plasma levels of mercaptopurine. Combination of methotrexate and mercaptopurine may therefore require dose adjustment.

The administration of asparaginase has been reported to antagonise the effects of methotrexate.

Skin cancer has been reported in a few patients with psoriasis or mycosis fungoides (a cutaneous T-cell lymphoma) receiving concomitant treatment with methotrexate plus PUVA therapy (methoxalen and ultraviolet light).

Care should be exercised whenever packed red blood cells and methotrexate are given concurrently. Patients receiving a 24 hour methotrexate infusion and subsequent transfusions have shown enhanced toxicity probably resulting from prolonged serum methotrexate concentrations.

Methotrexate is an immunosuppressant and may reduce immunological response to concurrent vaccination. Severe antigenic reactions may occur if a live vaccine is given concurrently.

**Incompatibilities.** Methotrexate has been reported to be incompatible with cytarabine, fluorouracil and prednisolone.

**ADVERSE REACTIONS**

Very common: greater than or equal to 1/10; common: greater than or equal to 1/100 and < 1/10; uncommon: greater than or equal to 1/1,000 and < 1/100; rare: greater than or equal to 1/10,000 and < 1/1,000 and very rare: < 1/10,000.

The major toxic effects of methotrexate occur on normal, rapidly proliferating tissues, particularly the bone marrow and gastrointestinal tract. Ulcerations of the oral mucosa are usually the earliest signs of toxicity. Ulcerative stomatitis, leucopenia, nausea and abdominal distress are the most common adverse reactions. Others reported include malaise, undue fatigue, chills and fever, dizziness, drowsiness, tinnitus, blurred vision, eye discomfort and decreased resistance to infection. The incidence and severity of side effects generally appear to be dose and frequency related. Adverse reactions have been reported for the various systems.
Skin. Dermatitis, erythematous rashes, erythema multiforme, pruritus, urticaria, photosensitivity, depigmentation/ hyperpigmentation, alopecia, vasculitis, petechiae, ecchymosis, telangiectasia, acne, folliculitis, furunculosis, nail changes. Burning and erythema may appear in psoriatic areas for one to two days following each dose. Rarely, painful plaque erosions may appear. Lesions of psoriasis may be aggravated by concomitant exposure to ultraviolet radiation. Skin ulceration has been reported in psoriatic patients. Anaphylactic reactions and skin ulceration/ necrosis consistent with toxic epidermal necrolysis, soft tissue necrosis and osteonecrosis have also been reported. Severe, occasionally fatal dermatological reactions, including toxic epidermal necrolysis, Stevens-Johnson syndrome, exfoliative dermatitis, skin necrosis and erythema multiforme have been reported in children and adults within days of administration. Reactions were noted after single or multiple low, intermediate or high doses of methotrexate in patients with neoplastic and nonneoplastic diseases.

Blood. Bone marrow depression, leucopenia, neutropenia, eosinophilia, pancytopenia, agranulocytosis, thrombocytopenia, anaemia (including aplastic anaemia), hypogammaglobulinaemia, decrease in serum albumin. Clinical sequelae such as fever, infections, haemorrhage from various sites and septicaemia lymphadenopathy and proliferative disorders may be expected. Megaloblastic anaemia has also been reported, mainly in elderly patients receiving long-term methotrexate therapy. Folate supplementation may permit continuation of methotrexate therapy with resolution of anaemia.

Cardiovascular. Pericarditis, vasculitis, pericardial effusion, hypotension and thromboembolic events (including arterial thrombosis, cerebral thrombosis, deep vein thrombosis, retinal vein thrombosis, thrombophlebitis and pulmonary embolus) have been reported with methotrexate therapy.

Alimentary system. Mucositis (gingivitis, pharyngitis, stomatitis, glossitis), anorexia, nausea, vomiting, diarrhoea, abdominal distress, haematemesis, melaena, gastrointestinal ulceration and bleeding, intestinal perforation, pancreatitis, enteritis, acute and chronic hepatic toxicity resulting in acute liver atrophy, necrosis, fatty metamorphosis, perirenal fibrosis, hepatic cirrhosis or elevated liver enzymes and decreased serum albumin and hepatic failure. In rare cases, the effect of methotrexate on the intestinal mucosa has led to malabsorption or toxic megacolon. Alteration of liver function tests (increases in transaminases and LDH levels) is commonly reported but usually resolves within one month of cessation of therapy.

Body as a whole: soft tissue necrosis, anaphylactoid reactions.

Genitourinary. Renal failure, dysuria, azotaemia, cystitis, haematuria, defective oogenesis or spermatogenesis, transient oligospermia, urogenital or menstrual dysfunction, infertility, abortion, foetal defects, foetal death, severe nephropathy, vaginitis, vaginal discharge.

Pulmonary. Interstitial pneumonitis deaths, interstitial fibrosis, and respiratory failure, reversible eosinophilic pulmonary infiltrates, chronic interstitial obstructive pulmonary disease, alveolitis, death. Manifestations of methotrexate induced pulmonary toxicity commonly include fever, cough (especially dry and nonproductive), dyspnoea, chest pain, hypoxaemia and/or radiological evidence of pulmonary infiltrates (usually diffuse and/or alveolar).

Central nervous system. Headaches, drowsiness, blurred vision. Aphasia, hemiparesis and convulsions and coma have occurred, possibly related to
haemorrhage or to complications from intra-arterial catheterisation. Following low
doses, occasional patients have reported transient subtle cognitive dysfunction,
mood alteration or unusual cranial sensations. Cognitive impairment has been
recorded in children who received intrathecal methotrexate together with cranial
irradiation. There have been reports of leucoencephalopathy following intravenous
administration of methotrexate in high doses to patients who have had craniospinal
irradiation. Serious neurotoxicity, frequently manifested as generalised or focal
seizures, has been reported with unexpectedly increased frequency among
paediatric patients with acute lymphoblastic leukaemia who were treated with
intermediate dose intravenous methotrexate (1 g/m²). Symptomatic patients were
commonly noted to have leucoencephalopathy, encephalopathy and/or
microangiopathic calcifications on diagnostic imaging studies.

After high dose use of methotrexate, the central nervous system toxicity which may
occur can be classified as follows:

1. chemical arachnoiditis manifested by such symptoms as headache, back
   pain, nuchal rigidity and fever;
2. paresis, usually transient, manifested by paraplegia and increased CSF
   pressure associated with involvement with one or more spinal roots;
3. a delayed syndrome occurring months to years after treatment characterised
   by necrotizing leucoencephalopathy and manifested by confusion, irritability,
   somnolence, ataxia, dementia, occasionally convulsions and rarely death. The
effects are dose related and occur particularly when intrathecal
methotrexate is given in combination with cranial irradiation and systemic
methotrexate therapy.

Ophthalmic. Conjunctivitis, eye discomfort, blurred vision and serious visual
changes of unknown aetiology including transient blindness have been reported in
patients receiving methotrexate.

Infections. There have been case reports of sometimes fatal opportunistic infections
in patients receiving methotrexate therapy for neoplastic and nonneoplastic diseases.
**Pneumonia (in some cases leading to respiratory failure) may occur.**
*Pneumocystis carinii* pneumonia was the most common infection. Other reported
infections include sepsis, nocardiosis, histoplasmosis, cryptococcosis, herpes zoster,
herpes simplex, hepatitis and disseminated herpes simplex, fatal sepsis and
cytomegalovirus, including cytomegaloviral pneumonia.

In the presence of active infection, Methotrexate should be used with extreme
caution. Methotrexate is usually contraindicated for patients with overt or
laboratory evidence of immunodeficiency syndromes.

Carcinogenicity. Cytotoxic medicines have been reported to be associated with an
increased risk of development of secondary tumours in humans. Evidence of
chromosomal damage to animal somatic cells and human bone marrow cells has
been reported with methotrexate. Reports of lymphoma, including reversible
lymphomas and tumour lysis syndrome have been documented in patients treated
with methotrexate.

Other. Other reactions related or attributed to the use of methotrexate, such as
metabolic changes, precipitation of diabetes, osteoporotic effects (including aseptic
necrosis of the femoral head), abnormal changes in tissue cells, arthralgia/myalgia,
proteinuria, nodulosis, stress fractures, loss of libido, impotence and even sudden
death, have been reported.
Radiation dermatitis and sunburn may be 'recalled'. A few cases of anaphylactoid reactions have been reported.
DOSAGE AND ADMINISTRATION

BECAUSE OF THE POTENTIAL TO CAUSE SEVERE TOXICITY, METHOTREXATE THERAPY REQUIRES CLOSE SUPERVISION.

Methotrexate Ebewe is suitable only for IV use. It should be diluted prior to administration. It is not suitable for intrathecal administration.

**Antineoplastic chemotherapy.** For conversion of mg/kg bodyweight to mg/m² of body surface area or the reverse, a ratio of 1:30 is given as a guideline. The conversion factor varies between 1:20 and 1:40 depending on age and body build.

**Breast carcinoma.** Prolonged cyclic combination chemotherapy with cyclophosphamide, methotrexate and fluorouracil has given good results when used as adjuvant treatment to radical mastectomy in primary breast cancer with positive axillary lymph nodes. Methotrexate dosage was 40 mg/m² intravenously on only the first and eighth days.

**Maintenance therapy for Leukaemia.** Acute lymphatic (lymphoblastic) leukaemia in children and young adolescents is the most responsive to present day chemotherapy. In young adults and older patients, clinical remission is more difficult to obtain and early relapse is more common. In chronic lymphatic leukaemia, the prognosis for adequate response is less encouraging. Methotrexate alone, or in combination with other agents, appears to be the medicine of choice for securing maintenance of medicine induced remissions. Methotrexate has been given in doses of 2.5 mg/kg intravenously every 14 days. If and when relapse does occur, reinduction of remission can again usually be obtained by repeating the initial induction regimen. Various experts have recently introduced a variety of dosage schedules for both induction and maintenance of remission with various combinations of alkylating and antifolate agents. Multiple medicine therapy with several agents, including methotrexate given concomitantly, is gaining increasing support in both the acute and chronic forms of leukaemia.

The prescriber should consult the appropriate scientific literature

Acute granulocytic leukaemia is rare in children but common in adults. This form of leukaemia responds poorly to chemotherapy and remissions are short with relapses common and resistance to therapy develops rapidly.

**High dose therapy (see Precautions).** Dosage regimens have varied considerably in different studies; the nature and severity of the disease and the previous experience of the investigator are some of the factors influencing the choice of dosage and the duration of therapy. It must be emphasised that high dosages should be used only by qualified specialists and in hospitals where the necessary facilities are available.

**Psoriasis chemotherapy.**

The patient should be fully informed of the risks involved and should be under constant supervision of the doctor.

Assessment of renal function, liver function and blood elements should be made by history, physical examination and laboratory tests (such as haemogram,
urinalysis, serum creatinine, liver function studies and liver biopsy if indicated) before beginning methotrexate, periodically during methotrexate therapy and before reinstituting methotrexate therapy after a rest period. Appropriate steps should be taken to avoid conception during and for at least three months following methotrexate therapy.

The commonly used injectable dosage schedule is by weekly parenteral intermittent large doses. The schedule should be continually tailored to the individual patient. Dose schedule cited below pertain to an average 70 kg adult. An initial test dose one week prior to initiation of therapy is recommended to detect any idiosyncrasy. A suggested dose range is 5 to 10 mg parenterally.

**Recommended starting dose.** Weekly single intravenous dose schedules: 10 to 25 mg per week until adequate response is achieved. With this dosage schedule, 50 mg per week should ordinarily not be exceeded.

Dosage may be gradually adjusted to achieve optimal clinical response, but not to exceed 50 mg. Once optimal clinical response has been achieved the dosage schedule should be reduced to the lowest possible amount of medicine and to the longest possible rest period. The use of methotrexate may permit the return to conventional topical therapy, which should be encouraged.

**Handling precautions.** As with all antineoplastic agents, trained personnel should prepare Methotrexate Injection BP. This should be performed in a designated area (preferably a cytotoxic laminar flow cabinet). The work surface should be protected by disposable plastic backed, absorbent paper. Protective gown, mask, gloves and appropriate eye protection should be worn when handling methotrexate. Where solution accidentally contacts skin or mucosa, the affected area should be immediately washed thoroughly with soap and water or sodium bicarbonate solution: Medical attention should be sought. It is recommended that pregnant personnel not handle cytotoxic agents such as methotrexate.

Luer-Lok fitting syringes are recommended. Large bore needles are recommended to minimise pressure and possible formation of aerosols. Aerosols may also be reduced by using a venting needle during preparation. Items used to prepare Methotrexate Injection BP, or articles associated with body waste, should be disposed of by placing in a double sealed polythene bag and incinerating at 1,100°C.

**Spills and disposal.** If spills occur, restrict access to the affected area. Wear two pairs of gloves (latex rubber), a respirator mask, a protective gown and safety glasses. Limit the spread of the spill by covering with absorbent material such as absorbent towel or adsorbent granules. Collect up the towel of absorbent/adsorbent material and other debris from spill and place in a leak proof plastic container and label accordingly. Cytotoxic waste should be regarded as hazardous or toxic and clearly labelled ‘CYTOTOXIC WASTE FOR INCINERATION AT 1,100°C’. Waste material should be incinerated at 1,100°C for at least one second. Cleanse the remaining spill area with copious amounts of water.

**OVERDOSAGE**
Contact the Poisons Information Centre on (telephone 0800 POISON or 0800 764766) for advice on management of overdose.

Discontinue methotrexate at the first sign of ulceration or bleeding, diarrhoea or marked depression of the haemopoietic system.
Symptoms commonly reported following oral overdose include those symptoms and signs reported at pharmacological doses, particularly haematological and gastrointestinal reactions. For example, leucopenia, thrombocytopenia, anaemia, pancytopenia, bone marrow suppression, mucositis, oral ulceration, nausea, vomiting, gastrointestinal ulceration, gastrointestinal bleeding. In some cases, no symptoms were reported. There have been reports of death following overdose. In these cases, events such as sepsis or septic shock, renal failure, and aplastic anaemia were also reported.

As soon as possible after an inadvertent overdosage of methotrexate, calcium folinate (leucovorin calcium) should be given at 10 mg/m\(^2\) IV or IM every 6 hours until the serum methotrexate levels are below \(10^{-8}\)M. In the presence of gastric stasis or obstruction, leucovorin should be administered parenterally. Concomitant hydration (3 L/day) and urinary alkalisation with sodium bicarbonate should be employed. The bicarbonate dose should be adjusted to maintain a urinary pH at 7 or greater. The use of acute, intermittent haemodialysis with a high-flux dialyzer should also be considered. Serum samples should be assayed for creatinine levels and methotrexate levels at 24 hour intervals. If the 24 hour serum creatinine level has increased 50% over baseline or if the 24 hour methotrexate level is > \(5 \times 10^{-6}\) M or the 48 hour methotrexate level is \(9 \times 10^{-7}\) M or higher, the doses of calcium folinate should be increased to 100 mg/m\(^2\) IV every three hours until the methotrexate level is < \(10^{-8}\) M. The infusion rate of calcium folinate should not exceed 16.0 mL (160 mg calcium folinate) per minute. Patients with significant third space accumulations should be considered high risk and monitored until serum methotrexate levels are < \(10^{-8}\) M regardless of their 24 hour serum concentration. The above mentioned statements on calcium folinate dosage do not apply with high dosage methotrexate therapy. The dosages of calcium folinate have varied in different studies and the published literature on high dosage methotrexate should be consulted.

In cases of massive overdosage, neither haemodialysis nor peritoneal dialysis have been shown to improve methotrexate elimination. However, effective clearance of methotrexate has been reported with acute, intermittent haemodialysis using a high flux dialyzer.

CAUTION: Because of its potential to cause severe toxicity, methotrexate therapy requires close supervision of the patient by the doctor.

PRESENTATION
Glass vial, 500mg/5mL: 1
Glass vial, 1000mg/10mL: 1
Glass vial, 5000mg/50mL: 1 (Oncology Pharmacy Bulk product)

STORAGE
Store below 25°C. Protect from light.

MEDICINE CLASSIFICATION
Prescription Medicine

NAME AND ADDRESS OF SPONSOR
Novartis New Zealand Ltd
PO Box 99102
Newmarket
Auckland 1149
Telephone 0800354 335

DATE OF PREPARATION

09 December 2014